IRIS
MORGILLO, Floriana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.697
NA - Nord America 7.602
AS - Asia 5.089
SA - Sud America 705
Continente sconosciuto - Info sul continente non disponibili 495
AF - Africa 68
OC - Oceania 13
Totale 26.669
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 7.903
US - Stati Uniti d'America 7.402
SG - Singapore 1.708
IT - Italia 1.326
IE - Irlanda 1.196
CN - Cina 1.102
HK - Hong Kong 823
VN - Vietnam 618
BR - Brasile 594
DE - Germania 476
GB - Regno Unito 474
UA - Ucraina 403
FR - Francia 295
KR - Corea 255
FI - Finlandia 157
SE - Svezia 144
IN - India 143
TR - Turchia 137
CA - Canada 118
JP - Giappone 100
GR - Grecia 98
NL - Olanda 45
AR - Argentina 40
AT - Austria 38
PK - Pakistan 38
BD - Bangladesh 37
MX - Messico 31
BE - Belgio 24
ID - Indonesia 21
ES - Italia 18
LT - Lituania 18
IQ - Iraq 17
PL - Polonia 17
CO - Colombia 16
EC - Ecuador 15
ZA - Sudafrica 14
CL - Cile 13
CH - Svizzera 12
PH - Filippine 12
CZ - Repubblica Ceca 10
VE - Venezuela 10
CR - Costa Rica 9
KE - Kenya 9
AE - Emirati Arabi Uniti 8
HN - Honduras 8
HU - Ungheria 8
AU - Australia 7
IR - Iran 7
MA - Marocco 7
PY - Paraguay 7
SA - Arabia Saudita 7
TN - Tunisia 7
TW - Taiwan 7
UZ - Uzbekistan 7
EG - Egitto 6
NZ - Nuova Zelanda 6
TT - Trinidad e Tobago 6
AL - Albania 5
AO - Angola 5
AZ - Azerbaigian 5
DZ - Algeria 5
EU - Europa 5
GT - Guatemala 5
IL - Israele 5
OM - Oman 5
SV - El Salvador 5
DO - Repubblica Dominicana 4
EE - Estonia 4
JO - Giordania 4
MK - Macedonia 4
NP - Nepal 4
PE - Perù 4
TH - Thailandia 4
GP - Guadalupe 3
JM - Giamaica 3
KZ - Kazakistan 3
MY - Malesia 3
PA - Panama 3
RO - Romania 3
SC - Seychelles 3
SN - Senegal 3
UY - Uruguay 3
BO - Bolivia 2
CG - Congo 2
CW - ???statistics.table.value.countryCode.CW??? 2
GA - Gabon 2
HR - Croazia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
Totale 26.163
Salva come PNG Salva come JPEG
Città #
Moscow 2.854
Dublin 1.188
San Jose 1.008
Hong Kong 807
Singapore 723
Santa Clara 691
Chandler 662
Jacksonville 633
Ashburn 587
Council Bluffs 452
Seoul 233
Naples 215
Beijing 198
Ho Chi Minh City 194
Princeton 174
Bremen 162
New York 157
Milan 150
Hanoi 140
Dallas 134
Medford 129
Ann Arbor 128
Hefei 125
Roxbury 125
Caserta 119
Munich 106
Los Angeles 98
Wilmington 90
Bengaluru 86
The Dalles 79
São Paulo 62
Boardman 60
Chicago 59
Nanjing 56
San Mateo 46
Woodbridge 45
Cambridge 44
Rome 40
Haiphong 39
Da Nang 38
Turku 38
Des Moines 37
Napoli 34
Houston 29
Miano 29
Nuremberg 29
Elora 28
Atlanta 26
Amsterdam 25
Brussels 24
Dong Ket 24
Rio de Janeiro 24
Brooklyn 22
Jinan 22
Orem 22
Tokyo 22
Vienna 21
Brasília 19
Frankfurt am Main 19
Helsinki 18
Mountain View 18
Shanghai 18
Tianjin 17
Montreal 16
Nanchang 16
Düsseldorf 15
Istanbul 15
North Bergen 15
Aiello Del Sabato 14
Aversa 14
Boston 14
Curitiba 14
London 14
Piscataway 14
Seattle 14
Toronto 14
Afragola 13
Norwalk 13
Warsaw 13
Belo Horizonte 12
Mumbai 12
Ercolano 11
Hải Dương 11
Ninh Bình 11
Phoenix 11
Zhengzhou 11
Columbus 10
Guarulhos 10
Lappeenranta 10
Auburn Hills 9
Brno 9
Falkenstein 9
Hangzhou 9
Miami 9
San Francisco 9
Thái Bình 9
Bahawalpur 8
Bogotá 8
Chennai 8
Cincinnati 8
Totale 13.933
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 262
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 221
ONCOLOGIA MEDICA 215
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 213
AXL is an oncotarget in human colorectal cancer 205
Adequacy of Cytologic Samples by Ultrasound-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology of Peripheral Pulmonary Nodules for Morphologic Diagnosis and Molecular Evaluations: Comparison With Computed Tomography-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology 205
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 201
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 201
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 200
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 199
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 198
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review 195
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 195
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 190
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 190
Chronic inflammation and oxidative stress in human carcinogenesis 188
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 186
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 182
Immunotherapy for head and neck cancer: Present and future 182
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 177
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 177
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 175
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 173
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 173
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 173
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 172
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 171
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 171
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 171
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 170
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 169
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 168
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 168
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold! 168
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 168
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 167
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 165
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 163
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 163
Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication(dagger) 162
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 161
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 161
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 160
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 158
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 156
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 156
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 155
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 155
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 154
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 154
PercuTwist tracheostomy in an intubated patient with tracheal stent 154
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 153
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 152
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 152
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 151
The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. 150
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 149
Pimasertib hydrochloride 149
Farmacogenomica e cancro colorettale 148
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 148
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 146
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 145
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 145
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 144
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 144
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. 143
Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up 142
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 142
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 142
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 141
TRASTUZUMAB RESISTANCE IN BREAST CANCER 141
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 140
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival 138
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 138
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 137
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 137
AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma 137
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 136
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 136
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 135
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 135
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 135
Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review 133
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 133
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 133
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 132
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 132
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 132
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 132
Targeting EGFR in Pancreatic Cancer Treatment. 131
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 131
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 131
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 130
Trimodality treatment in early-stage malignant pleural mesothelioma. Preliminary results of a multicenter phase II trial 129
Application of Telepathology for Rapid On-Site Evaluation of Touch Imprint Cytology in CT-Guided Percutaneous Transthoracic Core Needle Biopsy of Pulmonary Nodules: The Experience of Our Multidisciplinary Thoracic Tumor Board 128
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 127
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observation 127
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 127
PET-TC BODY CON FDG IN ONCOLOGIA 127
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 125
Totale 15.887
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.088 0 0 0 28 374 17 45 45 49 101 107 322
2022/20232.502 253 65 39 245 311 203 11 146 1.115 19 49 46
2023/2024935 82 34 43 55 291 132 18 26 16 18 74 146
2024/20253.049 33 62 30 77 453 402 397 261 438 412 260 224
2025/202613.475 516 605 653 619 1.053 7.361 781 733 487 361 179 127
2026/20272.400 182 405 860 953 0 0 0 0 0 0 0 0
Totale 26.669